Gecacitinib for preventing GVHD after stem cell transplant in myelofibrosis
Treatments studied
Part of Blood & lymphatic clinical trials.
This trial tests whether the drug gecacitinib can help prevent a serious complication called graft-versus-host disease (GVHD) after a stem cell transplant in people with myelofibrosis, a rare bone marrow disorder.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have primary or secondary myelofibrosis and are planning to have a stem cell transplant from a donor that is a matched unrelated, sibling, or half-matched family member.
- You are 18 years or older and willing to sign a consent form.
- You are able to swallow tablets and follow the study schedule.
- Your overall health is good, with a performance score of 60 or above on the Karnofsky scale (0-2 on the ECOG scale).
- You agree to use effective birth control if you or your partner can have children.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if taking Gecacitinib before, during, and after a stem cell transplant helps patients with myelofibrosis. The goal is to see if the drug can improve transplant outcomes and reduce complications.
This trial tests a new oral medication called Gecacitinib for people who have chronic graft-versus-host disease (cGVHD) after a stem cell transplant and whose cGVHD is not fully controlled or requires long-term steroids. It aims to see if Gecacitinib can help manage symptoms and reduce steroid use.
This trial tests a new drug, gecacitinib, for patients with moderate to severe chronic graft-versus-host disease (cGVHD) that has not improved after 2 to 5 prior treatments. It aims to see if the drug is safe and effective.
This trial tests a new drug called Gecacitinib for people who have acute graft-versus-host disease (a serious complication after a stem cell transplant) that did not get better with the standard second-line treatment, ruxolitinib. The goal is to see if Gecacitinib can help control the GVHD.
This study tests a new pill (gecacitinib) combined with steroids as the first treatment for moderate to severe acute graft-versus-host disease after a stem cell transplant. The goal is to see if this combination works better than steroids alone.
This trial tests if a drug called Ivarmacitinib can prevent graft-versus-host disease (a common complication where donor cells attack your body) after a stem cell transplant from a half-matched donor. It is for people with certain blood cancers who are about to receive a transplant.
Hear when a new aGVHD Prophylaxis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.